Concepedia

Author

Michael Kalos

University of PennsylvaniaORCID

Also Known As

Carl H. June, M Kalos, M. Kalos, Michael D. Kalos, Michael Kalos, Ruslan Novosiadly, Timothy M. Clay

244

Publications

26K

Citations

54

H-Index

90

Concepts

All Affiliations

University of PennsylvaniaChildren's Hospital of PhiladelphiaEli Lilly (United States)Fred Hutch Cancer CenterCancer Research Institute
MK

About

Michael Kalos is an author at University of Pennsylvania specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

28

12.2K

2

Health Sciences

2

2

86

3

Natural Sciences

2

2

27

4

Engineering

1

1

111

5

Allergy

1

1

42

Michael Kalos

×

77

Publications

24.1K

Citations

48

H-Index

YearCitations

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

David L. Porter, Bruce L. Levine, Michael Kalos,

New England Journal of Medicine

2011

3.5K

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp, Michael Kalos, David M. Barrett,

New England Journal of Medicine

2013

3.4K

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Michael Kalos, Bruce L. Levine, David L. Porter,

Science Translational Medicine

2011

2.4K

Gene Editing of <i>CCR5</i> in Autologous CD4 T Cells of Persons Infected with HIV

Pablo Tebas, David Stein, Winson W. Tang,

New England Journal of Medicine

2014

1.3K

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Gerald P. Linette, Edward A. Stadtmauer, Marcela V. Maus,

Blood

2013

1.1K

Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus,

Cancer Immunology Research

2013

847

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl,

Nature Medicine

2015

832

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons,

Nature

2018

829

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Brian Cameron, Andrew B. Gerry, Joseph Dukes,

Science Translational Medicine

2013

660

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

John Scholler, Troy Brady, Gwendolyn Binder-Scholl,

Science Translational Medicine

2012

640

Page 1